O
Onc.AI
AI-powered technology to bring clarity to cancer treatment decisions
About Onc.AI
Onc.AI is a private digital health startup that operates in the oncology sector. The company's primary objective is to enhance decision-making in cancer treatment through the use of artificial intelligence (AI). Onc.AI uses a comprehensive dataset from various sources such as diagnostic imaging, electronic medical records (EMR), labs, and genomics to develop AI models. These models aim to optimize precision oncology, a method of cancer treatment that uses genetic understanding to deliver effective, personalized care.
The company's initial product is designed to assist medical oncologists in making treatment decisions for metastatic lung cancer patients undergoing PD-1 immunotherapy. PD-1 immunotherapy is a type of treatment that helps the immune system fight cancer cells.
Onc.AI's business model revolves around the development and sale of these AI models to healthcare providers, particularly those specializing in oncology. The company generates revenue by selling access to these AI models, which help healthcare providers make more informed treatment decisions.
The team at Onc.AI is composed of successful entrepreneurs, healthcare technology operators, AI/ML researchers, and computer vision experts. The company operates remotely, allowing for a diverse and distributed team. The company culture emphasizes positivity, hard work, inclusivity, and kindness.
In summary, Onc.AI is a digital health startup that leverages AI to improve decision-making in oncology. It serves healthcare providers, operates in the healthcare technology market, and generates revenue by selling access to its AI models.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2020
- Headquarters
- Kelowna, Canada
- Employees
- 27
- Open positions
- None listed
- Dealroom signal
- 77.9/100
- Industry
- Health, Enterprise Software
- Sub-industry
- Health Platform
- Sector
- Health Tech & Medtech, Physician Support Tools
- Technology
- Artificial Intelligence
- Business model
- SaaS
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANT✓Other financing | Oct 2024 | $2M | — | National Cancer Institute | ↗ |
| SERIES A✓Equity / VC | Jan 2023 | $25M | $100M | Accomplice · KdT Ventures · Digitalis Ventures · LifeX Ventures | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Onc.AI is 5.8K monthly website visits, up 28.9% over the last three months. Onc.AI's team grew 12.5% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
National Cancer Institute
Series A10 investors entered at this stage
Accomplice
Blue Venture Fund
T. Chen Fong
Digitalis Ventures- JFJonathan Fleming
- SMStanley Marks
Frederic Kerrest
KdT Ventures
LifeX Ventures
Action Potential Venture Capital
Other known investors1 additional known investor
515 Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Onc.AI on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Onc.AI’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.